• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
Destruxin B

Destruxin B

Product ID D183745
Cas No. 2503-26-6
Purity ≥96%
Product Unit SizeCostQuantityStock
100 µg $102.00 In stock
1 mg $613.00 In stock
5 mg $2,453.00 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Destruxin B, a cyclic depsipeptide, is a secondary metabolite isolated from the fungus Metarhizium anisopliae. Each of the mycotoxins, destruxin A, B, and E, were individually found to display antitumor effects on leukemic cells in vitro. In addition, each destruxin was found to produce antiproliferative effects in colon cancer cells and to inhibit the migration and tube formation of human endothelial cells. Although the inhibition of vacuolar-type ATPase by destruxin B has been found to be weaker than bafilomycin A1, inhibition by destruxin B was found to be readily reversible, which makes it more useful as a probe of V-ATPase function. In human colorectal cancer cells destruxin B treatment resulted in suppressed proliferation and induced cell cycle arrest. Administration of destruxin B to human non-Hodgkin lumphoma cells resulted in apoptosis induced by attenuation of the mitochondrial membrane potential.

Product Info

Cas No.

2503-26-6

Purity

≥96%

Formula

C30H51N5O7

Formula Wt.

593.77

Chemical Name

Destruxin B

IUPAC Name

16-butan-2-yl-10,11,14-trimethyl-3-(2-methylpropyl)-13-propan-2-yl-4-oxa-1,8,11,14,17-pentazabicyclo[17.3.0]docosane-2,5,9,12,15,18-hexone

Synonym

MLS002702090; AC1L8LE6; MEGxm0_000393

Melting Point

230-240°C

Appearance

White powder

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

D183745 MSDS PDF

Info Sheet

D183745 Info Sheet PDF

References

Yeh CT, Rao YK, Ye M, et al. Preclinical evaluation of destruxin B as a novel Wnt signaling target suppressing proliferation and metastasis of colorectal cancer using non-invasive bioluminescence imaging. Toxicol Appl Pharmacol. 2012 May 15;261(1):31-41. PMID: 22465936.

Odier F, Vey A, Bureau JP. In vitro effect of fungal cyclodepsipeptides on leukemic cells: study of destruxins A, B, and E. Biol Cell. 1992;74(3):267-271. PMID: 1628110.

Dornetshuber-Fleiss R, Heffeter P, Mohr T, et al. Destruxins: fungal-derived cyclohexadepsipeptides with multifaceted anticancer and antiangiogenic activities. Biochem Pharmacol. 2013 Aug 1;86(3):361-377. PMID: 23747344.

Muroi M, Shiragami N, Takatsuki A. Destruxin B, a specific and readily reversible inhibitor of vacuolar-type H(+)-translocating ATPase. Biochem Biophys Res Commun. 1994 Dec 15;205(2):1358-1365. PMID: 7802670.

Chao PZ, Chin YP, Hsu IU, et al. Apoptotic toxicity of destruxin B in human non-Hodgkin lymphoma cells. Toxicol In Vitro. 2013 Sep;27(6):1870-1876. PMID: 23751424.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • E846184

    Everolimus EP Impurity B

    Everolimus impurity

    ≥96% (mix of E/Z)
  • P3469

    Pirfenidone

    Collagen synthesis inhibitor.

    ≥98%
  • S8013

    [Tyr8]-Substance P

    Endogenous tachykinin peptide, involved in infl...

    ≥95%
  • R1217

    RDEA119

    MEK1/2 inhibitor.

    ≥98%
  • P6977

    Pyr-GR-pNA

    Fluorogenic substrate used to measure serine pr...

    ≥98%
  • M3232

    Methylisoindigotin

    Indirubin derivative.

    ≥98%
  • A0778

    ABT-737

    BH3 mimetic; Bcl-2, Bxl-xl, Bcl-w inhibitor.

    ≥98%
  • L1044

    LCL-161

    SMAC mimetic; PXR agonist, IAP inhibitor.

    ≥99%, ≥99%ee, de
  • C2997

    Chymostatin

    Protease inhibitor.

    ≥95% (mixture of A, B, C)
  • F1652

    Fenbufen

    NSAID; COX-1/2 inhibitor.

    ≥98%
  • D564088

    10-Acetyl Docetaxel

    Docetaxel impurity

    ≥98%
  • P0397

    Pazopanib

    VEGFR, PDGFR, c-Kit inhibitor.

    ≥97%
  • D1644

    Deltorphin I

    Opioid peptide; δOR agonist.

    ≥98%
  • E9418

    Exendin 3 (9-39)

    Peptide, GLP-1 analog found in Heloderma; GLP-1...

    ≥95%
  • C4559

    Clomiphene Citrate

    Used for in vitro fertilization; FIASMA, SERM.<...

    ≥98%
  • F1895

    Fexofenadine Hydrochloride

    Histamine H1 antagonist.

    ≥98%
  • O7218

    Oseltamivir Phosphate

    Viral neuraminidase inhibitor, potential MAO-A ...

    ≥98%
  • M1644

    Meloxicam

    NSAID; COX-2 inhibitor.

    ≥98%
  • L493400

    LMK-235

    Selective HDAC4 and HDAC5 inhibitor.

    ≥98%
  • V0145

    Valinomycin

    Peptide, neutral ionophore.

    ≥98%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2026 LKT Laboratories, All Rights Reserved - Products for research use only